| Measuring securities litigation risk I Kim, DJ Skinner Journal of Accounting and Economics 53 (1-2), 290-310, 2012 | 854 | 2012 |
| A returns‐based representation of earnings quality F Ecker, J Francis, I Kim, PM Olsson, K Schipper The Accounting Review 81 (4), 749-780, 2006 | 363 | 2006 |
| Are sin stocks paying the price for accounting sins? I Kim, M Venkatachalam Journal of accounting, auditing & finance 26 (2), 415-442, 2011 | 218 | 2011 |
| Directors’ and officers’ insurance and opportunism in accounting choice I Kim Accounting & Taxation 7 (1), 51-65, 2015 | 51 | 2015 |
| Are sin stocks paying the price for their accounting sins I Kim, M Venkatachalam Unpublished working paper, Duke University, 2006 | 18 | 2006 |
| An analysis of the market reward and torpedo effect of firms that consistently meet expectations IY Kim Available at SSRN 314381, 2002 | 14 | 2002 |
| Predictive Ability of Directors’ and Officers’ Liability Insurance Coverage for Class Action Lawsuit Settlements IY Kim Accounting & Taxation 10 (1), 23-38, 2018 | 5 | 2018 |
| The role of directors' and officers' insurance in financial reporting and class action securities litigation IY Kim University of Michigan, 2004 | 4 | 2004 |
| POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada A Amadi, K Toor, E Keeney, H Thom, P Singh, I Kim, E Mameri Value in Health 25 (1), S40, 2022 | 1 | 2022 |
| Discussion—Organizational Structure and Earnings Management I Kim Journal of Accounting, Auditing & Finance 22 (2), 333-338, 2007 | 1 | 2007 |
| Implied biases in forecasts of earnings for different horizons M Deng, I Kim, J Yeo Working paper, Columbia Business School, 2006 | 1 | 2006 |
| HETERORHABDITIS BACTERIOPHORA NEMATODES ARE SENSITIVE TO THE BACTERIAL PATHOGEN PHOTORHABDUS ASYMBIOTICA I Kim, C Heryanto, I Eleftherianos The Journal of Parasitology 109 (1), 11-14, 2023 | | 2023 |
| EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France C Paul, M Massetti, FE Cotte, R Moreau, S Kassahun, P Singh, I Kim, ... Value in Health 25 (12), S180, 2022 | | 2022 |
| EE275 Number Needed to Treat Analysis of Nivolumab Versus Surveillance for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction … P Singh, S Kassahun, K Toor, I Kim, S Kakehi, E Estella-Pérez, ... Value in Health 25 (7), S387, 2022 | | 2022 |
| POSB38 Developing a Cost-Effectiveness Analysis for Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer … A Amadi, K Toor, E Keeney, H Thom, P Singh, I Kim, M Venkatachalam Value in Health 25 (1), S67, 2022 | | 2022 |
| PDB2 COMPARATIVE EFFICACY AND SAFETY OF PHARMACOTHERAPIES FOR THE TREATMENT OF OBESITY AMONG ADULTS: A SYSTEMATLIC LITERATURE AND NETWORK META-ANALYSIS K Toor, E Popoff, B Electricwala, I Kim, M Besada, S Cope Value in Health 22, S140, 2019 | | 2019 |
| Front & Back Matter M Le Bel, A Brunet, J Gosselin, J Merres, J Höss, LJ Albrecht, E Kress, ... Journal of Innate Immunity 6 (2), 2014 | | 2014 |
| School Address Home Address I KIM Ann Arbor MI 48109, 1234, 0 | | |
